# Tranexamic Acid versus Epsilon-Aminocaproic Acid in Total Knee Arthroplasty: A Meta-Analysis

Authors: Zhihui Li; Xiaotong Sun; Weihua Li; Minghui Zhang
Journal: Journal of Healthcare Engineering
 (2021)

---

## Abstract

Objective. At present, the effect of tranexamic acid (TXA) and epsilon-aminocaproic acid (EACA) on total knee arthroplasty (TKA) remains controversial. Therefore, the aim of this meta-analysis is to compare the differences between the effects of TXA and EACA in TKA. Methods. We used electronic databases, including PubMed, Embase, MEDLINE, Ovid, ScienceDirect, Cochran Library, Google Scholar, clinical trial, and Chinese related databases, for literature search to find any effect of TXA and EACA in TKA. The differences between groups were compared by odds ratio (OR), weighted mean difference (WMD), and 95% confidence interval (CI). A total of four studies, including 3 randomized controlled trials (RCT) and 1 cohort study, were involved in this meta-analysis, involving 1836 participants. Among these participants, 816 belonged to the TXA group and 1020 belonged to the EACA group. Results. Meta-analysis indicated no difference in surgery time (WMD = 0.01, 95% CI −0.35 to 0.36), total amount of blood loss (WMD = 0.14, 95% CI −0.09 to 0.37), transfusion rate (OR = 0.74, 95% CI 0.20 to 2.78), transfusion units per patient (SMD = −0.15, 95% CI −0.54 to 0.25), complications (OR = 0.75, 95% CI 0.37 to 1.55), and length of stay (SMD = −0.01, 95% CI −0.11 to 0.08). Conclusions. Our results suggest that the effect of TXA is not superior to EACA in TKA. However, this conclusion still needs to be further confirmed by multicenter and large-sample clinical trials.


---

## Body

## 1. Introduction

Total knee arthroplasty (TKA) is the most effective and widely used surgical method for the treatment of patients with advanced osteoarthritis [1–3]. For patients with significantly narrowed femoral and tibial gaps in the lower extremity knee joint and severely worn cartilage layer accompanied by extremity deformities, TKA has a meaningful effect. TKA could not only relieve the patient’s arthritis pain but also provide a safe and effective treatment for the recovery of knee joint function [4, 5]. At present, with the acceleration of the aging of the population, the number of people affected by arthritis is increasing, and the number of patients receiving TKA is also growing.It is well known that during the TKA process, there might be a large amount of blood loss, resulting in an increased rate of blood transfusion [6, 7]. The disadvantage of blood transfusion is that it may cause severe immune response, intravascular hemolysis, disease transmission, acute renal failure, and coagulopathy [8–11], resulting in prolonged hospital stay, increased risk of infection at the surgical site, and even death. To reduce intraoperative blood loss and blood transfusion rates, medical researchers have developed several clinical strategies, including hypotension control [12], administration of local anesthesia [13] and erythropoietin [14], lowering the blood transfusion threshold [15], and utilizing antifibrinolytic agents [16].Antifibrinolytic agents are usually used in clinical practice to enhance hemostasis and could effectively reduce the amount of bleeding during the TKA process, thereby reducing the incidence of blood transfusion and postoperative complications [17]. Tranexamic acid (TXA) and epsilon-aminocaproic acid (EACA) are commonly used antifibrinolytic agents. Previous studies have revealed that both TXA and EACA could decrease the amount of blood loss and transfusion rate in the TKA process, thereby improving the patient’s prognosis [18–20]. However, there is still controversy regarding the efficacy of TXA and EACA in TKA. Camarasa et al. [21] and Boese et al. [22] found that TXA and EACA had no statistical difference in reducing the bleeding volume and blood transfusion rate during the TKA process. However, evidence from a cohort study demonstrated that although EACA was comparable to TXA in reducing blood loss and length of hospital stay, EACA has a lower cost [23]. On the other hand, a recent randomized controlled trial (RCT) found that EACA was associated with increased perioperative blood loss compared to TXA in the TKA process [24].To resolve above controversy, our study used a meta-analysis method to compare the effectiveness of TXA and EACA in TKA and provide a theoretical basis for clinical treatment.


## 2. Methods

This study has been approved by the ethics committee of Beihua University.


### 2.1. Inclusion Criteria

Studies were included if (1) they had patients undergoing TKA; (2) used TXA and EACA in TKA; (3) they were RCTs or cohort studies; (4) they were published in Chinese or English; and (5) they did not put restriction on the gender or geographic location of the study population.


### 2.2. Exclusion Criteria

Studies were excluded if they had (1) patients with coagulopathy; (2) patients with myocardial infarction or cardiac stent implantation; (3) patients with cerebrovascular accident; (4) patients with venous thrombosis or pulmonary embolism; (5) patients treated with non-steroidal anti-inflammatory drugs or platelet anticoagulation; (6) patients with severe liver and kidney dysfunction; and (7) incomplete data or data that could not be extracted for analysis.


### 2.3. Literature Retrieval Strategy

Databases used included PubMed, Embase, MEDLINE, Ovid, ScienceDirect, Cochran Library, Google Scholar, clinical trial, and Chinese related databases (including Chinese Biomedical Database, China National Knowledge Infrastructure, Weipu Database, and Wanfang Database). The literature search included studies where TXA and EACA were used for TKA, and the search time was between the date of the establishment of the database to May 1, 2020. In order to further expand the scope of retrieval, manually retrieved references were included in the literature to obtain more relevant literature. We used the combination of medical subject headings (MESH) and non-MESH to investigate relevant literature. The MESH and non-MESH are as follows: (“Tranexamic Acid” or “AMCHA” or “trans-4-(Aminomethyl) cyclohexanecarboxylic Acid” or “t-AMCHA” or “AMCA” or “Anvitoff” or “Cyklokapron” or “Ugurol” or “KABI 2161” or “Spotof” or “Transamin” or “Amchafibrin” or “Exacyl”) and (“Aminocaproic Acid” or “6-Aminohexanoic Acid” or “6 Aminohexanoic Acid” or “epsilon-Aminocaproic Acid” or “epsilon Aminocaproic Acid” or “6-Aminocaproic Acid” or “6 Aminocaproic Acid” or “Capralense” or “Capramol” or “Caproamin” or “Caprocid” or “Hexalense” or “CY-116” or “Epsamon” or “Epsikapron” or “Hemocaprol” or “Amicar” or “Caprolest”) and (“total knee arthroplasty” or “Knee Replacement Arthroplasties” or “knee Replacement Arthroplasty” or “Knee Arthroplasty, Total” or “Total Knee Arthroplasty” or “Knee Replacement, Total” or “Arthroplasties, Knee Replacement” or “Replacement Arthroplasty, Knee”).


### 2.4. Outcomes

We extracted the outcome indicators that could be combined in the included studies, including surgery time, total blood loss, transfusion, transfusion units per patient, complications, and length of stay.


### 2.5. Literature Screening and Data Extraction

Two researchers independently screened the literature, extracted the data, and did the cross-checking. In case of disagreement, a third party was consulted to get assistance in judgment. The missing data were supplemented as much as possible by contacting the original author. In the literature screening process, the titles and abstracts were screened first, followed by exclusion of obvious irrelevant literature, and further screening of full text to determine inclusion of the study in this meta-analysis. The information extracted mainly included the following: study authors, years of publication, country of publication, type of study, time of patient recruitment, type of surgery, age of patients, proportion of women, method of drug use, and dosage.


### 2.6. Quality Evaluation of Included Literature

For RCT, two investigators conducted quality evaluation according to the Cochrane Handbook [25]; for cohort studies, the Newcastle–Ottawa Scale (NOS) [26] was used for quality evaluation.


### 2.7. Statistical Analysis

Meta-analysis of the included literature was carried out using Stata 11 software. Odds ratio (OR) was the effect indicator for counting data, and weighted mean difference (WMD) was the effect indicator for measurement data. Each effect quantity gives its point estimate and 95% confidence interval (CI).I2 was used to examine the heterogeneity among the included literatures (the test level was α = 0.05). In this study, the random-effects model was used for summary analysis. Obvious heterogeneity was managed by sensitivity analysis or descriptive analysis.


## 2.1. Inclusion Criteria

Studies were included if (1) they had patients undergoing TKA; (2) used TXA and EACA in TKA; (3) they were RCTs or cohort studies; (4) they were published in Chinese or English; and (5) they did not put restriction on the gender or geographic location of the study population.


## 2.2. Exclusion Criteria

Studies were excluded if they had (1) patients with coagulopathy; (2) patients with myocardial infarction or cardiac stent implantation; (3) patients with cerebrovascular accident; (4) patients with venous thrombosis or pulmonary embolism; (5) patients treated with non-steroidal anti-inflammatory drugs or platelet anticoagulation; (6) patients with severe liver and kidney dysfunction; and (7) incomplete data or data that could not be extracted for analysis.


## 2.3. Literature Retrieval Strategy

Databases used included PubMed, Embase, MEDLINE, Ovid, ScienceDirect, Cochran Library, Google Scholar, clinical trial, and Chinese related databases (including Chinese Biomedical Database, China National Knowledge Infrastructure, Weipu Database, and Wanfang Database). The literature search included studies where TXA and EACA were used for TKA, and the search time was between the date of the establishment of the database to May 1, 2020. In order to further expand the scope of retrieval, manually retrieved references were included in the literature to obtain more relevant literature. We used the combination of medical subject headings (MESH) and non-MESH to investigate relevant literature. The MESH and non-MESH are as follows: (“Tranexamic Acid” or “AMCHA” or “trans-4-(Aminomethyl) cyclohexanecarboxylic Acid” or “t-AMCHA” or “AMCA” or “Anvitoff” or “Cyklokapron” or “Ugurol” or “KABI 2161” or “Spotof” or “Transamin” or “Amchafibrin” or “Exacyl”) and (“Aminocaproic Acid” or “6-Aminohexanoic Acid” or “6 Aminohexanoic Acid” or “epsilon-Aminocaproic Acid” or “epsilon Aminocaproic Acid” or “6-Aminocaproic Acid” or “6 Aminocaproic Acid” or “Capralense” or “Capramol” or “Caproamin” or “Caprocid” or “Hexalense” or “CY-116” or “Epsamon” or “Epsikapron” or “Hemocaprol” or “Amicar” or “Caprolest”) and (“total knee arthroplasty” or “Knee Replacement Arthroplasties” or “knee Replacement Arthroplasty” or “Knee Arthroplasty, Total” or “Total Knee Arthroplasty” or “Knee Replacement, Total” or “Arthroplasties, Knee Replacement” or “Replacement Arthroplasty, Knee”).


## 2.4. Outcomes

We extracted the outcome indicators that could be combined in the included studies, including surgery time, total blood loss, transfusion, transfusion units per patient, complications, and length of stay.


## 2.5. Literature Screening and Data Extraction

Two researchers independently screened the literature, extracted the data, and did the cross-checking. In case of disagreement, a third party was consulted to get assistance in judgment. The missing data were supplemented as much as possible by contacting the original author. In the literature screening process, the titles and abstracts were screened first, followed by exclusion of obvious irrelevant literature, and further screening of full text to determine inclusion of the study in this meta-analysis. The information extracted mainly included the following: study authors, years of publication, country of publication, type of study, time of patient recruitment, type of surgery, age of patients, proportion of women, method of drug use, and dosage.


## 2.6. Quality Evaluation of Included Literature

For RCT, two investigators conducted quality evaluation according to the Cochrane Handbook [25]; for cohort studies, the Newcastle–Ottawa Scale (NOS) [26] was used for quality evaluation.


## 2.7. Statistical Analysis

Meta-analysis of the included literature was carried out using Stata 11 software. Odds ratio (OR) was the effect indicator for counting data, and weighted mean difference (WMD) was the effect indicator for measurement data. Each effect quantity gives its point estimate and 95% confidence interval (CI).I2 was used to examine the heterogeneity among the included literatures (the test level was α = 0.05). In this study, the random-effects model was used for summary analysis. Obvious heterogeneity was managed by sensitivity analysis or descriptive analysis.


## 3. Results

### 3.1. Literature Search Process

A total of 375 related literatures were initially obtained. After reading the title, abstract, and full text, four studies were finally included in this meta-analysis, including three RCTs and one cohort study, involving 1836 participants. Among them, 816 participants belonged to the TXA group and 1020 belonged to the EACA group. The flowchart of literature retrieval is shown in Figure1, and the basic features of the included literature are presented in Table 1.Figure 1
The flowchart of literature retrieval.Table 1
Basic characteristics of included literature.
AuthorsYearCountryType of studyPeriod of enrollmentType of surgeryTXA groupEACA groupAgeFemale (%)TXA usageAgeFemale (%)EACA usageCamarasa2006SpainRCTFrom March 2004 to March 2005TKA73 (61–84)74.3TXA 10 mg·kg−1 i.v. just before the tourniquet was deflated and 3 h later.73 (59–80)87.5EACA 100 mg kg−1 before tourniquet deflation followed by continuous perfusion (1 g/h−1) during 3 h.Churchill2017USANon-RCTBetween April 1, 2012, and December 31, 2014TKA65.8 (11.09)64.3A single 1 g infusion of TXA or when EACA is used, 5 g infusion done for patients weighing 50 kg or less, or 10 g done for patients weighing more than 50 kg.63.9 (10.29)64.3A single 1 g infusion of TXA or when EACA used, 5 g infusion done for patients weighing 50 kg or less, or 10 g done for patients weighing more than 50 kg.Boese2017USARCTFrom January 2014 to December 2015TKA64.97 ± 9.5970.4The regimen for TXA was 1 g in 250 mL of saline solution given over 30 minutes prior to inflating the tourniquet and making the initial incision. A second 1 g in 250 mL of saline solution was infused over 30 minutes beginning at the time of wound closure.66.12 ± 9.7374.0The regimen for EACA was 7 g in 250 mL of saline solution given over 30 minutes just prior to inflating the tourniquet and making the initial incision. A second 7 g of EACA in 250 mL of saline solution was infused over 30 minutes beginning at the time of wound closure.Bradley2019USARCTBetween February 2015 and December 2017TKA64.7 (60.7–69.6)68.5The first dose was given immediately before making the incision and a second dose was given during wound closure. TXA was given as 1 g intravenously in two doses.65.6 (58.8 to 69.4)58.3The first dose was given immediately before making the incision and a second dose was given during wound closure. EACA was given as a 5 g dose in 250 ml of normal saline.RCT = randomized controlled trial; TKA = total knee arthroplasty; TXA = tranexamic acid; EACA = epsilon-aminocaproic acid.


### 3.2. Literature Quality Evaluation

The quality evaluation of the three RCTs is shown in Figure2. The NOS score of the cohort study was 7.Figure 2
The quality evaluation of the three RCTs.


### 3.3. Surgery Time

Two studies involving 261 participants described surgery time. Among them, 133 participants were in the TXA group and 128 were in the EACA group. Meta-analysis showed that compared with TXA, EACA did not significantly reduce surgery time (WMD = 0.01, 95% CI −0.35 to 0.36, I2 = 44.4%) (Figure 3), suggesting no difference between the effect of TXA and EACA on surgery time.Figure 3
Comparison of surgery time between tranexamic acid and epsilon-aminocaproic acid.


### 3.4. Total Blood Loss

Three studies involving 399 participants described total blood loss. Among them, 203 participants were in the TXA group and 196 were in the EACA group. Comprehensive analysis demonstrated that compared with TXA, EACA did not remarkably reduce total blood loss (WMD = 0.14, 95% CI −0.09 to 0.37, I2 = 23.1%) (Figure 4), indicating that TXA is not superior in efficacy to EACA in reducing total blood loss.Figure 4
Comparison of total blood loss between tranexamic acid and epsilon-aminocaproic acid.


### 3.5. Transfusion Rate

Three studies involving 1642 participants described transfusion rates. Among them, there were 718 participants in the TXA group and 924 participants in the EACA group. Of the patients in the TXA group, 25 received transfusion treatment, while 28 of 924 patients in the EACA group received transfusion treatment. Meta-analysis indicated that compared with TXA, EACA did not notably reduce transfusion rate (OR = 0.74, 95% CI 0.20 to 2.78, I2 = 40.2%) (Figure 5).Figure 5
Comparison of transfusion rate between tranexamic acid and epsilon-aminocaproic acid.


### 3.6. Transfusion Units per Patient

Two studies involving 1497 participants described transfusion units per patient. Among them, 645 participants were in the TXA group and 852 were in the EACA group. The results of meta-analysis displayed that compared with TXA, EACA did not significantly reduce the transfusion units per patient (SMD = −0.15, 95% CI − 0.54 to 0.25, I2 = 64.9%) (Figure 6). Considering that only two studies were included, we did not conduct sensitivity analysis. The obvious heterogeneity may be caused by different research types.Figure 6
Comparison of transfusion units per patient between tranexamic acid and epsilon-aminocaproic acid.


### 3.7. Complications

Two studies involving 339 participants described the complications. Among the participants, there were 171 in the TXA group and 168 in the EACA group. Complications occurred in 15 patients in the TXA group and 19 patients in the EACA group. Summary analysis demonstrated that compared with TXA, EACA did not reduce the incidence of complications (OR = 0.75, 95% CI 0.37 to 1.55, I2 = 0.0%) (Figure 7).Figure 7
Comparison of complications between tranexamic acid and epsilon-aminocaproic acid.


### 3.8. Length of Stay

Three studies involving 1766 participants described the length of stay. Among the participants, 778 were in the TXA group and 988 were in the EACA group. The results of meta-analysis indicated that compared with TXA, EACA did not decrease the length of stay (SMD = −0.01, 95% CI −0.11 to 0.08, I2 = 0.0%) (Figure 8).Figure 8
Comparison of length of stay between tranexamic acid and epsilon-aminocaproic acid.


## 3.1. Literature Search Process

A total of 375 related literatures were initially obtained. After reading the title, abstract, and full text, four studies were finally included in this meta-analysis, including three RCTs and one cohort study, involving 1836 participants. Among them, 816 participants belonged to the TXA group and 1020 belonged to the EACA group. The flowchart of literature retrieval is shown in Figure1, and the basic features of the included literature are presented in Table 1.Figure 1
The flowchart of literature retrieval.Table 1
Basic characteristics of included literature.
AuthorsYearCountryType of studyPeriod of enrollmentType of surgeryTXA groupEACA groupAgeFemale (%)TXA usageAgeFemale (%)EACA usageCamarasa2006SpainRCTFrom March 2004 to March 2005TKA73 (61–84)74.3TXA 10 mg·kg−1 i.v. just before the tourniquet was deflated and 3 h later.73 (59–80)87.5EACA 100 mg kg−1 before tourniquet deflation followed by continuous perfusion (1 g/h−1) during 3 h.Churchill2017USANon-RCTBetween April 1, 2012, and December 31, 2014TKA65.8 (11.09)64.3A single 1 g infusion of TXA or when EACA is used, 5 g infusion done for patients weighing 50 kg or less, or 10 g done for patients weighing more than 50 kg.63.9 (10.29)64.3A single 1 g infusion of TXA or when EACA used, 5 g infusion done for patients weighing 50 kg or less, or 10 g done for patients weighing more than 50 kg.Boese2017USARCTFrom January 2014 to December 2015TKA64.97 ± 9.5970.4The regimen for TXA was 1 g in 250 mL of saline solution given over 30 minutes prior to inflating the tourniquet and making the initial incision. A second 1 g in 250 mL of saline solution was infused over 30 minutes beginning at the time of wound closure.66.12 ± 9.7374.0The regimen for EACA was 7 g in 250 mL of saline solution given over 30 minutes just prior to inflating the tourniquet and making the initial incision. A second 7 g of EACA in 250 mL of saline solution was infused over 30 minutes beginning at the time of wound closure.Bradley2019USARCTBetween February 2015 and December 2017TKA64.7 (60.7–69.6)68.5The first dose was given immediately before making the incision and a second dose was given during wound closure. TXA was given as 1 g intravenously in two doses.65.6 (58.8 to 69.4)58.3The first dose was given immediately before making the incision and a second dose was given during wound closure. EACA was given as a 5 g dose in 250 ml of normal saline.RCT = randomized controlled trial; TKA = total knee arthroplasty; TXA = tranexamic acid; EACA = epsilon-aminocaproic acid.


## 3.2. Literature Quality Evaluation

The quality evaluation of the three RCTs is shown in Figure2. The NOS score of the cohort study was 7.Figure 2
The quality evaluation of the three RCTs.


## 3.3. Surgery Time

Two studies involving 261 participants described surgery time. Among them, 133 participants were in the TXA group and 128 were in the EACA group. Meta-analysis showed that compared with TXA, EACA did not significantly reduce surgery time (WMD = 0.01, 95% CI −0.35 to 0.36, I2 = 44.4%) (Figure 3), suggesting no difference between the effect of TXA and EACA on surgery time.Figure 3
Comparison of surgery time between tranexamic acid and epsilon-aminocaproic acid.


## 3.4. Total Blood Loss

Three studies involving 399 participants described total blood loss. Among them, 203 participants were in the TXA group and 196 were in the EACA group. Comprehensive analysis demonstrated that compared with TXA, EACA did not remarkably reduce total blood loss (WMD = 0.14, 95% CI −0.09 to 0.37, I2 = 23.1%) (Figure 4), indicating that TXA is not superior in efficacy to EACA in reducing total blood loss.Figure 4
Comparison of total blood loss between tranexamic acid and epsilon-aminocaproic acid.


## 3.5. Transfusion Rate

Three studies involving 1642 participants described transfusion rates. Among them, there were 718 participants in the TXA group and 924 participants in the EACA group. Of the patients in the TXA group, 25 received transfusion treatment, while 28 of 924 patients in the EACA group received transfusion treatment. Meta-analysis indicated that compared with TXA, EACA did not notably reduce transfusion rate (OR = 0.74, 95% CI 0.20 to 2.78, I2 = 40.2%) (Figure 5).Figure 5
Comparison of transfusion rate between tranexamic acid and epsilon-aminocaproic acid.


## 3.6. Transfusion Units per Patient

Two studies involving 1497 participants described transfusion units per patient. Among them, 645 participants were in the TXA group and 852 were in the EACA group. The results of meta-analysis displayed that compared with TXA, EACA did not significantly reduce the transfusion units per patient (SMD = −0.15, 95% CI − 0.54 to 0.25, I2 = 64.9%) (Figure 6). Considering that only two studies were included, we did not conduct sensitivity analysis. The obvious heterogeneity may be caused by different research types.Figure 6
Comparison of transfusion units per patient between tranexamic acid and epsilon-aminocaproic acid.


## 3.7. Complications

Two studies involving 339 participants described the complications. Among the participants, there were 171 in the TXA group and 168 in the EACA group. Complications occurred in 15 patients in the TXA group and 19 patients in the EACA group. Summary analysis demonstrated that compared with TXA, EACA did not reduce the incidence of complications (OR = 0.75, 95% CI 0.37 to 1.55, I2 = 0.0%) (Figure 7).Figure 7
Comparison of complications between tranexamic acid and epsilon-aminocaproic acid.


## 3.8. Length of Stay

Three studies involving 1766 participants described the length of stay. Among the participants, 778 were in the TXA group and 988 were in the EACA group. The results of meta-analysis indicated that compared with TXA, EACA did not decrease the length of stay (SMD = −0.01, 95% CI −0.11 to 0.08, I2 = 0.0%) (Figure 8).Figure 8
Comparison of length of stay between tranexamic acid and epsilon-aminocaproic acid.


## 4. Discussion

In this investigation, we used a meta-analysis method to evaluate the efficacy of TXA and EACA in patients undergoing TKA. We found that (1) there was no remarkable difference between the efficacy of the two drugs in surgery time (WMD = 0.01, 95% CI −0.35 to 0.36, I2 = 44.4%); (2) TXA was not superior to EACA (WMD = 0.14, 95% CI −0.09 to 0.37) in terms of total blood loss; (3) TXA and EACA had similar effect on transfusion rate and transfusion units per patient; (4) there was no significant difference in complications between the two groups (OR = 0.75, 95% CI 0.37 to 1.55); and (5) there was no significant difference in length of stay between the two groups (SMD = −0.01, 95% CI −0.11 to 0.08).TKA is an operative procedure for end-stage knee osteoarthritis and other knee diseases [27, 28]. For end-stage knee osteoarthritis patients, it could effectively eradicate the pain and greatly improve the quality of life. At present, with better economy and medical expertise, more and more patients with end-stage knee joint disease have received a TKA surgery [29, 30]. However, the prognosis of patients receiving TKA is closely related to total blood loss during and after TKA. Previous studies [31, 32] have shown that TKA can lead to blood loss of 300 ml to 1000 ml, even up to 2000 ml, causing severe hypothrombinemia and even hemorrhagic shock and death. Therefore, it is important for clinicians to find effective strategies to reduce the amount of blood loss during TKA and then reduce the rate of blood transfusion and improve the prognosis of patients.Currently, an important strategy to reduce bleeding during TKA is to use antifibrinolytic agents. TXA and EACA are commonly used as antifibrinolytic agents in clinical practice. However, the efficacy of the two drugs is controversial, and there are only few studies comparing TXA and EACA directly in TKA. An RCT involving 127 patients revealed that the use of TXA and EACA reduced blood loss in patients who had undergone TKA, but there was no notable difference between the two groups [21]. Similarly, another RCT also suggested that the effect of TXA and EACA on TKA is similar [22]. On the other hand, a cohort study found that while the effect of EACA on TKA is comparable to that of TXA, the cost of EACA is lower than that of TXA, making EACA a more favorable agent. However, a recently published RCT showed that EACA was related to increased perioperative blood loss compared to TXA in patients undergoing TKA, suggesting that EACA is also not ideal for use in TKA. In this meta-analysis, through the integrated analysis of the above four articles, we found that no statistical difference exists between the effect of TXA and EACA in patients undergoing TKA, suggesting that either of the two agents can be used in patients undergoing TKA. It should be noted, however, that EACA is more favorable than TXA in terms of cost [33, 34]. Therefore, considering the medical burden, EACA might be more appropriate for patients undergoing TKA. It should be emphasized that although the cost of EACA is insignificant for the total price of TKA, considering annual increase in the number of patients undergoing TKA surgery and that TKA is one of the common operative procedures in hospitals, the accumulated savings annually will be important to consider.This meta-analysis has the following limitations. First, three RCTs and one cohort study were involved in this study. In view of the small number of current articles, subgroup analysis was not performed according to the research type. Second, as can be seen in Table1, most of the articles included came from the United States, while data from Europe and Asia are limited. Whether the results of this study are applicable to other regions of the world or populations still needs to be confirmed by additional studies. Third, for transfusion units per patient, the heterogeneity between the groups was apparent (I2 = 64.9%). However, due to the lack of studies, we were unable to conduct sensitivity analysis or subgroup analysis to explore the source of the heterogeneity. Fourth, as can be seen in Table 1, TXA and EACA were administered at the set time and dose, but there were slight differences in the method of administration and dose between each study, which may partially explain the heterogeneity between studies and benefit-cost. Finally, it should be emphasized that only one of the included studies reported costs and is not yet globally representative. Due to the differences of country, region, labor cost, and medical security system, the cost-effectiveness of TXA and EACA still needs to be further confirmed by more studies.In conclusion, our results suggest that the effect of TXA is not superior to EACA in TKA. However, this finding still needs to be further confirmed by multicenter and large-sample clinical trials.



---

*Source: 1758066-2021-11-03.xml*